Sponsors Like START Rare Disease Pilot, Will Prasad Maintain Its Momentum?

 
• By Kate Rawson
  
Before resigning as CBER director, Peter Marks said he thought the Trump Administration would continue supporting rare disease drug development. (Shutterstock)

More from Cell & Gene Therapies

More from United States